MCID: AST007
MIFTS: 66

Astrocytoma

Categories: Neuronal diseases, Cancer diseases

Aliases & Classifications for Astrocytoma

MalaCards integrated aliases for Astrocytoma:

Name: Astrocytoma 12 72 28 51 41 14 69
Cerebral Astrocytoma 12 69
Astrocytoma, No Icd-O Subtype 12
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 41 D001254

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astocyte cells, a type of star-shaped glial cell, located in the cerebrum.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to fibrillary astrocytoma and cerebellar astrocytoma. An important gene associated with Astrocytoma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Afinitor and Temodar have been mentioned in the context of this disorder. Affiliated tissues include the cerebrum, brain and spinal cord, and related phenotypes are Decreased cell migration and Decreased sensitivity to paclitaxel

Wikipedia : 72 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 434)
# Related Disease Score Top Affiliating Genes
1 fibrillary astrocytoma 34.4 GFAP IDH1 KIAA1549 MGMT TP53
2 cerebellar astrocytoma 34.2 IDH1 KIAA1549 TP53
3 pilocytic astrocytoma of cerebellum 34.0 IDH1 KIAA1549 NF1
4 spinal cord astrocytoma 33.9 GFAP IDH1 MGMT TP53
5 protoplasmic astrocytoma 33.9 GFAP TP53
6 juvenile pilocytic astrocytoma 33.9 CDKN2A GFAP NF1 TP53
7 oligoastrocytoma 33.5 GFAP MGMT
8 pilocytic astrocytoma 33.5 CDK4 CDKN2A GFAP IDH1 KIAA1549 KRAS
9 grade iii astrocytoma 33.4 CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
10 pleomorphic xanthoastrocytoma 32.6 GFAP IDH1 MGMT TP53
11 brain stem astrocytic neoplasm 32.5 CDKN2A TP53
12 li-fraumeni syndrome 32.2 CDKN2A EGFR IDH1 MDM2 NF1 PTEN
13 glioblastoma multiforme 31.2 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
14 meningioma, familial 31.0 GFAP NF1 PTEN TP53
15 ependymoma 30.9 EGFR GFAP MGMT NES
16 ganglioglioma 30.9 GFAP NES TP53
17 medulloblastoma 30.8 DMBT1 GFAP MGMT NES TP53
18 anaplastic oligodendroglioma 30.7 CDKN2A EGFR IDH1 MGMT
19 dysembryoplastic neuroepithelial tumor 30.7 GFAP IDH1 NES
20 oligodendroglioma 30.7 CDKN2A EGFR GFAP IDH1 MGMT OLIG2
21 glioma 30.6 CCND1 CDK4 CDKN2A DMBT1 EGFR IDH1
22 hydrocephalus 30.6 GFAP NES PTEN TP53
23 gliofibroma 30.6 GFAP NF1 TP53
24 glioblastoma 30.5 CCND1 CDK4 CDKN2A DMBT1 EGFR IDH1
25 melanoma, cutaneous malignant 1 30.5 CDK4 CDKN2A MGMT PTEN TP53
26 retinoblastoma 30.5 CCND1 CDK4 CDKN2A MDM2 TP53
27 adenoma 30.4 CCND1 KRAS MGMT TP53
28 mixed glioma 30.3 GFAP IDH1 TP53
29 chordoma 30.2 CDKN2A EGFR GFAP
30 small cell carcinoma 30.1 EGFR PTEN TP53
31 adenocarcinoma 30.1 CCND1 CDKN2A EGFR KRAS TP53 VEGFA
32 papilloma 30.1 CCND1 CDKN2A PTEN TP53
33 cowden syndrome 1 30.1 EGFR PTEN
34 pleomorphic adenoma 30.0 GFAP MDM2 TP53
35 tanycytic ependymoma 30.0 GFAP NES OLIG2
36 leukemia, acute myeloid 30.0 CDKN2A IDH1 KRAS MDM2 TP53
37 gliosarcoma 29.9 CDK4 EGFR GFAP IDH1 MGMT NES
38 neurilemmoma 29.9 GFAP NES NF1
39 optic nerve glioma 29.9 GFAP NES NF1 TP53
40 giant cell glioblastoma 29.9 EGFR GFAP IDH1 MDM2 MGMT PTEN
41 myeloma, multiple 29.9 CCND1 CDK4 CDKN2A TP53 VEGFA
42 von hippel-lindau syndrome 29.9 CCND1 NF1 VEGFA
43 basal cell carcinoma 29.8 CCND1 CDKN2A PTEN TP53
44 hemangioma 29.8 KRAS PTEN VEGFA
45 malignant glioma 29.8 CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
46 gliomatosis cerebri 29.6 EGFR GFAP IDH1 MDM2 NES PTEN
47 nervous system cancer 29.6 CCND1 CDK4 CDKN2A GFAP MDM2 NF1
48 bladder cancer 29.4 CCND1 CDK4 CDKN2A EGFR KRAS MDM2
49 brain cancer 29.0 DMBT1 EGFR GFAP IDH1 MGMT NES
50 breast cancer 28.8 CCND1 CDK4 EGFR KRAS MDM2 NF1

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

GenomeRNAi Phenotypes related to Astrocytoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 CDK4 EGFR ITGB1 KRAS NF1
2 Decreased sensitivity to paclitaxel GR00112-A-0 8.62 NF1 PTEN

MGI Mouse Phenotypes related to Astrocytoma:

43 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 ITGB1 KRAS MDM2 NF1 TP53 PTEN
2 behavior/neurological MP:0005386 10.48 ITGB1 KRAS KIAA1549 NF1 MDM2 OLIG2
3 growth/size/body region MP:0005378 10.47 ITGB1 KRAS IDH1 NF1 MDM2 OLIG2
4 homeostasis/metabolism MP:0005376 10.47 KIAA1549 ITGB1 KRAS NF1 MGMT MDM2
5 immune system MP:0005387 10.43 KIAA1549 ITGB1 KRAS MDM2 NF1 TP53
6 digestive/alimentary MP:0005381 10.42 ITGB1 KRAS MDM2 NF1 TP53 PTEN
7 cardiovascular system MP:0005385 10.41 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
8 mortality/aging MP:0010768 10.41 ITGB1 KRAS IDH1 NF1 MGMT MDM2
9 endocrine/exocrine gland MP:0005379 10.38 ITGB1 KRAS MDM2 NF1 MGMT PTEN
10 embryo MP:0005380 10.35 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
11 hematopoietic system MP:0005397 10.35 ITGB1 IDH1 MDM2 KRAS NF1 PTEN
12 neoplasm MP:0002006 10.32 ITGB1 KRAS MGMT MDM2 NF1 TP53
13 nervous system MP:0003631 10.3 ITGB1 KRAS MDM2 NF1 OLIG2 NRN1
14 integument MP:0010771 10.29 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
15 muscle MP:0005369 10.27 ITGB1 KRAS MDM2 NF1 TP53 PTEN
16 craniofacial MP:0005382 10.22 ITGB1 MDM2 KRAS NF1 VEGFA TP53
17 liver/biliary system MP:0005370 10.22 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
18 limbs/digits/tail MP:0005371 10.14 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
19 normal MP:0002873 10.14 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
20 no phenotypic analysis MP:0003012 10.09 KRAS MDM2 MGMT OLIG2 NRN1 VEGFA
21 hearing/vestibular/ear MP:0005377 10.06 ITGB1 KRAS NF1 TP53 DMBT1 EGFR
22 pigmentation MP:0001186 10.02 ITGB1 KRAS MDM2 NF1 TP53 PTEN
23 renal/urinary system MP:0005367 10.02 ITGB1 KRAS MDM2 NF1 PTEN VEGFA
24 reproductive system MP:0005389 9.96 ITGB1 MDM2 KRAS PTEN VEGFA TP53
25 respiratory system MP:0005388 9.93 ITGB1 KRAS MGMT NF1 TP53 PTEN
26 skeleton MP:0005390 9.73 ITGB1 KRAS IDH1 MDM2 NF1 OLIG2
27 vision/eye MP:0005391 9.4 ITGB1 KRAS NF1 TP53 PTEN OLIG2

Drugs & Therapeutics for Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 45 EVEROLIMUS Novartis March 2009
2
Temodar 17 45 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 594)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
6
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
7 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
11 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 38904 498142
15
Cyclophosphamide Approved, Investigational Phase 2, Phase 3, Phase 1 50-18-0, 6055-19-2 2907
16
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
17
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
18 Thiotepa Approved, Investigational Phase 2, Phase 3, Phase 1 52-24-4 5453
19
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
20
Tranexamic Acid Approved Phase 3 1197-18-8 5526
21
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
22
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
23
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
24
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
25
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
26
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
27
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
28
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
29
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
30
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
31
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
32
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
33
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
34
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 216974-75-3
35
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
36
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
37
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
38
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2 106-60-5 137
39
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
40
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
41
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
42
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
43
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5282379 5538
44
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
46
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
47
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
48
Ondansetron Approved Phase 3 99614-02-5 4595
49
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
50
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719

Interventional clinical trials:

(show top 50) (show all 1399)

# Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
4 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
5 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
8 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
9 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
10 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
12 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
13 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
14 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
15 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
16 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
17 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
18 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
19 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
20 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
21 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
22 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
23 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
24 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
25 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
26 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
27 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
28 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
29 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
30 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
31 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
32 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
33 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
34 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3 hCRF;placebo hCRF
35 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
36 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
37 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
38 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
39 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
40 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
41 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
42 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
43 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
44 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
45 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
46 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
47 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
48 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
49 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
50 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

# Genetic test Affiliating Genes
1 Astrocytoma 28

Anatomical Context for Astrocytoma

The Foundational Model of Anatomy Ontology organs/tissues related to Astrocytoma:

18
The Cerebrum

MalaCards organs/tissues related to Astrocytoma:

38
Brain, Spinal Cord, T Cells, Endothelial, Bone, Testes, Breast

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 2288)
# Title Authors Year
1
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( 29393182 )
2018
2
iASPP, a microRNAa89124 target, is aberrantly expressed in astrocytoma and regulatesA malignantA gliomaA cellA migration and viability. ( 29257240 )
2018
3
Expression of CD133 as a Putative Prognostic Biomarker to Predict Intracranial Dissemination of Primary Spinal Cord Astrocytoma. ( 29180077 )
2018
4
Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. ( 29330645 )
2018
5
Efficacy and safety of everolimus in patients younger than 12a8^months with congenital subependymal giant cell astrocytoma. ( 29395661 )
2018
6
Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. ( 29171168 )
2018
7
Management and survival of adult patients with pilocytic astrocytoma in the National Cancer Database. ( 29427814 )
2018
8
Mitogen-activated protein kinase in gliosis and pilocytic astrocytoma. ( 29168690 )
2018
9
Supratentorial extension of large cerebellar pilocytic astrocytoma in adult. ( 29446978 )
2018
10
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
11
Long-Term Remission of Recurrent Brainstem Pilocytic Astrocytoma with Neuraxis Dissemination Using Recombinant Human Endostatin After Failure of Vincristine and Carboplatin. ( 29203315 )
2018
12
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. ( 29230924 )
2018
13
MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating I^-catenin and causing activation of FOXO3a. ( 29399110 )
2018
14
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. ( 28993887 )
2018
15
A low-grade astrocytoma in a sixteen-year-old boy with a 7q11.22 deletion. ( 29445462 )
2018
16
Effect of brefelamide on proliferation of 1321N1 human astrocytoma cells induced by glial cell line-derived neurotrophic factor. ( 29441947 )
2018
17
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. ( 29444314 )
2018
18
Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. ( 29180079 )
2018
19
Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report. ( 29451453 )
2018
20
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. ( 27718322 )
2017
21
Retinal Metastases From Anaplastic Astrocytoma. ( 28864383 )
2017
22
Pilocytic astrocytoma: A rare presentation as intraventricular tumor. ( 28680735 )
2017
23
Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. ( 28699883 )
2017
24
Case Report: Low-Grade Astrocytoma Within A Mature Cystic Teratoma In An Adolescent Patient. ( 29107097 )
2017
25
Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades. ( 27789731 )
2017
26
Desmoplastic infantile astrocytoma and ganglioglioma: case report and review of the literature. ( 27668845 )
2017
27
Correlative analyses of the expression levels of PIAS3, p-SHP2, SOCS1 and SOCS3 with STAT3 activation in human astrocytomas. ( 28035384 )
2017
28
Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome. ( 28968151 )
2017
29
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. ( 28124097 )
2017
30
Midbrain Gliofibroma Presenting in Adulthood following "Cure" of a Childhood Intraventricular Pilocytic Astrocytoma. ( 28245445 )
2017
31
The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ( 28775924 )
2017
32
Recurrent Optic Nerve Pilocytic Astrocytoma: A Rare Case. ( 28658822 )
2017
33
Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation. ( 28074282 )
2017
34
Tyrosine receptor kinase B is a drug target in astrocytomas. ( 27402815 )
2017
35
Crossed Aphasia in a Patient with Anaplastic Astrocytoma of the Non-Dominant Hemisphere. ( 29299104 )
2017
36
Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. ( 28567590 )
2017
37
Solitary primary leptomeningeal astrocytoma - An extremely rare pathology. ( 28681779 )
2017
38
Combination of AQP1 and I^-catenin expression is an independent prognosis factor in astrocytoma patients. ( 29245912 )
2017
39
Nucleolar and spindle associated protein 1 promotes the aggressiveness of astrocytoma by activating the Hedgehog signaling pathway. ( 28899410 )
2017
40
Axial MR diffusion tensor imaging and tractography in clinical diagnosed and pathology confirmed cervical spinal cord astrocytoma. ( 28320182 )
2017
41
Correction: A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. ( 28880959 )
2017
42
Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus. ( 29277498 )
2017
43
Fluorescence guided resection with 5-aminolevulinic acid of a pilomyxoid astrocytoma of the third ventricle. ( 28495088 )
2017
44
A Novel Variant of OCT4 Entitled OCT4B3 is Expressed in Human Bladder Cancer and Astrocytoma Cell Lines. ( 28706610 )
2017
45
Pilocytic astrocytoma of the cerebellopontine angle mimicking vestibular schwannoma: report of a rare entity. ( 29278012 )
2017
46
Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. ( 28516078 )
2017
47
Anaplastic astrocytoma with aquaporin-4 positive in CSF: A case report. ( 29390462 )
2017
48
Unusual Occurrence of Multifocal Desmoplastic Infantile Astrocytoma: A Case Report and Review of the Literature. ( 28222441 )
2017
49
Hydrocephalus associated with spinal intramedullary pilocytic astrocytoma. ( 28484535 )
2017
50
Intramedullary Thoracic Spine Astrocytoma Presenting as Hydrocephalus in an Infant: A Case Report. ( 28848162 )
2017

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
3 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
5 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
6 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
7 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
8 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113

Cosmic variations for Astrocytoma:

9 (show top 50) (show all 2018)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10672 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade I c.577C>T p.H193Y 5
2 COSM40802 ZW10 central nervous system,brain,glioma,astrocytoma Grade IV c.2140C>T p.P714S 4
3 COSM40801 ZSWIM4 central nervous system,brain,glioma,astrocytoma Grade IV c.266C>T p.P89L 4
4 COSM39611 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade IV c.393A>T p.G131G 4
5 COSM40237 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.3651C>T p.T1217T 4
6 COSM39318 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.2044T>A p.C682S 4
7 COSM39317 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.2043G>C p.Q681H 4
8 COSM39149 ZNF507 central nervous system,brain,glioma,astrocytoma Grade IV c.1517G>C p.R506T 4
9 COSM40794 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.42C>T p.D14D 4
10 COSM39217 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2162T>G p.V721G 4
11 COSM40504 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2176G>A p.D726N 4
12 COSM39507 ZMAT4 central nervous system,brain,glioma,astrocytoma Grade IV c.76G>A p.E26K 4
13 COSM40870 ZFC3H1 central nervous system,brain,glioma,astrocytoma Grade IV c.1055G>A p.S352N 4
14 COSM40793 ZFAT central nervous system,brain,glioma,astrocytoma Grade IV c.1006G>A p.V336M 4
15 COSM40680 ZEB1 central nervous system,brain,glioma,astrocytoma Grade IV c.1913C>T p.S638L 4
16 COSM41152 ZC3H6 central nervous system,brain,glioma,astrocytoma Grade IV c.2254G>T p.G752* 4
17 COSM40778 ZBTB4 central nervous system,brain,glioma,astrocytoma Grade IV c.2842C>T p.L948F 4
18 COSM40777 ZBTB24 central nervous system,brain,glioma,astrocytoma Grade IV c.1886C>T p.P629L 4
19 COSM39508 ZBTB21 central nervous system,brain,glioma,astrocytoma Grade IV c.997G>A p.G333S 4
20 COSM40776 ZBTB16 central nervous system,brain,glioma,astrocytoma Grade IV c.413C>T p.A138V 4
21 COSM41039 YWHAH central nervous system,brain,glioma,astrocytoma Grade IV c.169C>T p.R57* 4
22 COSM40774 YTHDC2 central nervous system,brain,glioma,astrocytoma Grade IV c.782C>T p.A261V 4
23 COSM39272 XPO7 central nervous system,brain,glioma,astrocytoma Grade IV c.1157G>A p.R386Q 4
24 COSM40772 XPO1 central nervous system,brain,glioma,astrocytoma Grade IV c.1147G>A p.E383K 4
25 COSM21780 XAB2 central nervous system,brain,glioma,astrocytoma Grade IV c.849C>A p.I283I 4
26 COSM39469 WNK2 central nervous system,brain,glioma,astrocytoma Grade IV c.3757G>A p.A1253T 4
27 COSM40770 WNK1 central nervous system,brain,glioma,astrocytoma Grade IV c.5293G>A p.G1765S 4
28 COSM40769 WFS1 central nervous system,brain,glioma,astrocytoma Grade IV c.573G>A p.K191K 4
29 COSM40767 WEE1 central nervous system,brain,glioma,astrocytoma Grade IV c.765G>A p.K255K 4
30 COSM40766 WDTC1 central nervous system,brain,glioma,astrocytoma Grade IV c.1118C>T p.A373V 4
31 COSM40765 WDR70 central nervous system,brain,glioma,astrocytoma Grade IV c.463G>A p.E155K 4
32 COSM40764 WDR6 central nervous system,brain,glioma,astrocytoma Grade IV c.1170C>T p.F390F 4
33 COSM40761 WDR34 central nervous system,brain,glioma,astrocytoma Grade IV c.1484C>T p.T495I 4
34 COSM40762 WDR34 central nervous system,brain,glioma,astrocytoma Grade IV c.475G>A p.A159T 4
35 COSM39468 WDR24 central nervous system,brain,glioma,astrocytoma Grade IV c.790C>T p.R264C 4
36 COSM40758 WDFY3 central nervous system,brain,glioma,astrocytoma Grade IV c.1126C>T p.H376Y 4
37 COSM39888 WBP1L central nervous system,brain,glioma,astrocytoma Grade IV c.490C>T p.P164S 4
38 COSM40234 WASHC4 central nervous system,brain,glioma,astrocytoma Grade IV c.367+1G>A p.? 4
39 COSM40754 VPS45 central nervous system,brain,glioma,astrocytoma Grade IV c.370G>A p.E124K 4
40 COSM40753 VPS41 central nervous system,brain,glioma,astrocytoma Grade IV c.1830G>A p.Q610Q 4
41 COSM39977 VPS13B central nervous system,brain,glioma,astrocytoma Grade IV c.1913C>T p.T638I 4
42 COSM41129 VPS13B central nervous system,brain,glioma,astrocytoma Grade IV c.9845A>C p.K3282T 4
43 COSM40751 VPS13A central nervous system,brain,glioma,astrocytoma Grade IV c.7400G>A p.G2467D 4
44 COSM40750 VN2R1P central nervous system,brain,glioma,astrocytoma Grade IV c.1753C>T p.P585S 4
45 COSM40748 VIPR2 central nervous system,brain,glioma,astrocytoma Grade IV c.598G>A p.V200M 4
46 COSM39478 VIPAS39 central nervous system,brain,glioma,astrocytoma Grade IV c.1200G>C p.K400N 4
47 COSM6506659 VHL central nervous system,brain,glioma,astrocytoma Grade IV c.385C>G p.L129V 4
48 COSM39246 VEGFD central nervous system,brain,glioma,astrocytoma Grade IV c.694A>G p.K232E 4
49 COSM40746 VDR central nervous system,brain,glioma,astrocytoma Grade IV c.1135C>T p.L379F 4
50 COSM40744 VCPIP1 central nervous system,brain,glioma,astrocytoma Grade IV c.3601G>A p.E1201K 4

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

Pathways related to Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
2
Show member pathways
13.11 EGFR ITGB1 KRAS MDM2 PTEN TP53
3
Show member pathways
13.03 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
4
Show member pathways
13.01 CCND1 CDK4 EGFR ITGB1 KRAS MDM2
5
Show member pathways
12.97 CCND1 EGFR ITGB1 KRAS PTEN VEGFA
6
Show member pathways
12.82 CCND1 CDK4 CDKN2A EGFR KRAS PTEN
7 12.8 EGFR KRAS NF1 TP53 VEGFA
8 12.79 CCND1 CDK4 CDKN2A EGFR ITGB1 KRAS
9
Show member pathways
12.77 EGFR ITGB1 KRAS NF1 VEGFA
10
Show member pathways
12.77 EGFR KRAS MDM2 PTEN TP53
11
Show member pathways
12.75 CCND1 EGFR ITGB1 KRAS PTEN VEGFA
12
Show member pathways
12.73 CCND1 CDK4 MDM2 MGMT TP53
13
Show member pathways
12.65 CCND1 CDK4 KRAS PTEN TP53 VEGFA
14
Show member pathways
12.64 CCND1 CDK4 CDKN2A MDM2 TP53
15
Show member pathways
12.62 CCND1 CDK4 CDKN2A EGFR KRAS MDM2
16 12.59 CCND1 CDK4 CDKN2A MDM2 MGMT TP53
17
Show member pathways